Axogen Inc vs Nike Inc — how do they compare? Axogen Inc trades at $38.78 (market cap $2.06B), while Nike Inc trades at $42.93 (market cap $63.47B). The key difference: Nike Inc is far larger — about 30.8× Axogen Inc's market cap, and Nike Inc pays a 3.83% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | NKE | |
|---|---|---|
Market Cap | $2.06B | $63.47B |
Sector | Technology | Consumer Cyclical |
52-Week High | $46.19 | $79.24 |
52-Week Low | $11.28 | $40.75 |
Enterprise Value | $1.98B | $65.48B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.83% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Nike (NKE) trades at $43.76, down 1.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $46.31B for 2025 with a net income margin of 6.7%, though earnings have beaten expectations in recent quarters. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting potential upside from current levels.
Nike's outlook is supported by strong brand equity and consistent earnings beats, but faces headwinds from softer demand in China and margin pressure. The stock presents a value opportunity with a P/E of 20.41 below historical averages, though execution risks in the turnaround strategy remain key for investor confidence.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →